- Meeting abstract
- Open Access
Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: a controlled study in critically ill patients
Critical Care volume 1, Article number: P040 (1997)
To evaluate the differences in administered in a lipid emulsion compared to amphotericin B (AmpoB) in dextrose 5%, for the treatment of Candida albicans infection.
Sixty consecutive critically ill patients with confirmed or suspected Candida infection received AmphoB (1 mg/kg/24 h) administered randomly in either dextrose 5% (group A) or in lipid emulsion (20% Intralipid®) (group B).
Measurements and main results
Clinical tolerance (fever, chills, hemodynamics), liver function tests, electrolytes and coagulation profile were evaluated. Patients receiving AmphoB in lipid emulsion experienced a lower incidence of drug-associated fever (61.4% versus 5.8%, P < 0.003), rigors (54% versus 8.5%, P < 0.004), hypotension (17% versus 0%) and nephrotoxicity. Significant thrombocytopenia (264,500 ± 71,460/mm3 to 163,570 ± 34,450/mm3, P < 0.01), not associated with active bleeding, occurred with AmphoB-lipid emulsion but not with the dextrose regimen.
Treatment with AmphoB-lipid emulsion of critically ill patients with Candida infection seems to be safer and as effective as the conventional mode of administration.
About this article
Cite this article
Sorkine, P., Nagar, H., Weinbroum, A. et al. Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: a controlled study in critically ill patients. Crit Care 1, P040 (1997). https://doi.org/10.1186/cc46
- Liver Function
- Emergency Medicine
- Lower Incidence